Uncategorized

FDA issues warning letter after GLP-1 manufacturer refuses inspectors access

Published

5 hours ago

on

New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version